- Home
- WHF vs GLSI Comparison
WHF vs GLSI Comparison
Compare WHF & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- GLSI
- Stock Information
- Founded
- WHF 2011
- GLSI 2006
- Country
- WHF United States
- GLSI United States
- Employees
- WHF N/A
- GLSI N/A
- Industry
- WHF Finance Companies
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- GLSI Health Care
- Exchange
- WHF Nasdaq
- GLSI Nasdaq
- Market Cap
- WHF 162.2M
- GLSI 145.2M
- IPO Year
- WHF 2012
- GLSI 2020
- Fundamental
- Price
- WHF $7.02
- GLSI $8.39
- Analyst Decision
- WHF Hold
- GLSI Strong Buy
- Analyst Count
- WHF 3
- GLSI 1
- Target Price
- WHF $9.17
- GLSI $39.00
- AVG Volume (30 Days)
- WHF 149.6K
- GLSI 86.7K
- Earning Date
- WHF 11-10-2025
- GLSI 11-14-2025
- Dividend Yield
- WHF 25.36%
- GLSI N/A
- EPS Growth
- WHF N/A
- GLSI N/A
- EPS
- WHF 0.42
- GLSI N/A
- Revenue
- WHF $76,339,000.00
- GLSI N/A
- Revenue This Year
- WHF N/A
- GLSI N/A
- Revenue Next Year
- WHF N/A
- GLSI N/A
- P/E Ratio
- WHF $16.60
- GLSI N/A
- Revenue Growth
- WHF N/A
- GLSI N/A
- 52 Week Low
- WHF $6.39
- GLSI $7.88
- 52 Week High
- WHF $11.31
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- WHF 47.32
- GLSI 36.12
- Support Level
- WHF $6.39
- GLSI $7.94
- Resistance Level
- WHF $7.40
- GLSI $8.95
- Average True Range (ATR)
- WHF 0.23
- GLSI 0.58
- MACD
- WHF -0.00
- GLSI 0.01
- Stochastic Oscillator
- WHF 61.88
- GLSI 22.16
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.